van der Kleij Maud B A, Bruijn Tristan V M, Kalicharan Raween W, Elshot Yannick S, Pilon Maxime C F, Oostdijk Mark, Tibben Matthijs M, Nuijen Bastiaan, Huitema Alwin D R, Rustemeyer Thomas, Steeghs Neeltje
Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Cancer Rep (Hoboken). 2025 Jun;8(6):e70238. doi: 10.1002/cnr2.70238.
Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re-introduction of imatinib after a hypersensitivity reaction should be considered.
Here we present a case report of a 68-year-old patient with a GIST diagnosis who was re-introduced to imatinib after a type IV hypersensitivity reaction via desensitization. A desensitization plan, a plan for formulation of low-dose imatinib capsules, and the essential steps when considering desensitization are discussed.
Our case of a patient with a type IV hypersensitivity reaction after starting imatinib treatment demonstrates that desensitization is a feasible option after serious cutaneous adverse events in specific cases, when done with good interdisciplinary collaboration and clinical management.
伊马替尼治疗已被批准用于多种适应症，包括慢性粒细胞白血病（CML）和胃肠道间质瘤（GIST）。虽然不良事件很常见，但过敏反应并不常见。由于伊马替尼治疗有明确的临床益处，因此在过敏反应后应考虑重新引入伊马替尼。
在此，我们报告一例68岁诊断为GIST的患者，在发生IV型过敏反应后通过脱敏重新引入伊马替尼。讨论了脱敏计划、低剂量伊马替尼胶囊的配制计划以及考虑脱敏时的基本步骤。
我们的病例显示，一名患者在开始伊马替尼治疗后发生IV型过敏反应，这表明在特定病例中，当通过良好的多学科协作和临床管理进行脱敏时，脱敏是严重皮肤不良事件后的一种可行选择。
